Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 52 of 116

  1. High-Low Dose Radiotherapy

    Jian Li

    Nasopharyngeal Carcinoma (NPC)

    phase 2 other active

    1 trial

  2. Homoharringtonine

    Teva Pharma GmbH

    Myeloid Leukemia, Chronic

    phase 2 small molecule terminated

    1 trial

  3. Humanized CD7 CAR-T cells

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  4. Hydrogen Peroxide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Hyperbolic

    Talion

    non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. Hyperpolarized 13C-Pyruvate injection

    Hospital Authority, Hong Kong

    Gynecologic Cancer

    phase 2 small molecule active

    1 trial

  7. Hypofractionated radiation/chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  8. I3Y-MC-JPCS

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  9. IAH0968

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 2 mab active

    1 trial

  10. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  11. IAP0971

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  12. IB 2018-04

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  13. IB 2019-01

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  14. IB 2019-03

    The George Institute

    Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.

    phase 2 small molecule active

    1 trial

  15. IB 2019-04

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  16. IB 2019-07

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  17. IB 2020-02

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  18. IB 2020-05

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  19. IB 2021-01

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  20. IB 2021-03

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  21. IB 2023-02

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  22. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  23. IBB0979

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. IBI363

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  25. IBRUTINIB

    Fondazione Telethon ETS

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like monoclonal B-cell lymphocytosis

    phase 2 small molecule active

    1 trial

  26. IC 2019-02

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  27. IC 2020-06

    The George Institute

    Metastatic uveal melanoma

    phase 2 other active

    1 trial

  28. IC 2022-07

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  29. IC 2024-01

    The George Institute

    HER3-mutant and HER2-not amplified metastatic breast cancer

    phase 2 small molecule active

    1 trial

  30. ICO-2023-10

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  31. ICO-2023-14

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  32. ICO-N-2013-03

    CERO THERAPEUTICS HOLDINGS, INC.

    Breast cancer

    phase 2 small molecule active

    1 trial

  33. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  34. IDE196-009

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  35. IDE574

    IDEAYA Biosciences

    ER+, HER 2- Breast Cancer

    phase 2 small molecule active

    1 trial

  36. IDE849

    IDEAYA Biosciences

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  38. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Unresectable/metastatic Small cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  39. IFCT-1904

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  40. IFCT-2003

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  41. IFCT-2101

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  42. IFCT-2401 SPORADIC

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  43. IFCT-2502

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  44. IFG-05-2019

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

  45. IFOM-CPT008/2022/PO0

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  46. IGEV

    Fudan University

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  47. IIT2024097

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML (Acute Myelogenous Leukemia)

    phase 2 small molecule active

    1 trial

  48. IJB-LBC-NEOCHECK2018

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.